Program
BI 1815368
A development code. Also written as “BI 1815368 (C-14)”, “BI 1815368 (C-13)” and “BI 1815368 formulation 1”.
In Boehringer Ingelheim's pipeline, Oral vascular modulator
. Its studies are mostly in Macular Edema, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 71 open or running | phase 2since Apr 30, 2025 | Apr 14, 2022 | Mar 1, 2028phase 2 · NCT06962839 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 1815368
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2022First study: phase 1 study in HealthyFirst studyNCT05337592 · 72 enrolled · Germany
- May 5, 2023Phase 1 study in HealthyNCT05857878 · 59 enrolled · Belgium
- Jul 19, 2023Phase 1 study in HealthyNCT05965583 · 14 enrolled · Germany
- Jul 3, 2024Phase 1 study in HealthyNCT06494774 · 26 enrolled · Japan
- Oct 22, 2024Phase 1 study in HealthyNCT06655220 · 14 enrolled · Germany
- Apr 30, 2025Phase 2 study in Macular EdemaNCT06962839 · 300 planned · United States, China, Czechia and more
- Jul 3, 2026Phase 1 study in HealthyNCT07693218 · 8 enrolled · Netherlands
- Oct 16, 2026Primary completion moved from 2027-09-01 to 2028-03-01Date moved laterphase 2 · +6 months · NCT06962839
Ahead
- Mar 1, 2028Primary completion: phase 2 study in Macular EdemaNCT06962839
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Oral vascular modulator”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07693218Healthy · Netherlands | 1 | Completed | Aug 29, 2026 | 8 |
| NCT06962839Macular Edema · United States, China, Czechia and more | 2 | Recruiting | Mar 1, 2028 | 300 |
| NCT06655220Healthy · Germany | 1 | Completed | Dec 8, 2024 | 14 |
| NCT06494774Healthy · Japan | 1 | Completed | Nov 13, 2024 | 26 |
| NCT05965583Healthy · Germany | 1 | Completed | Oct 24, 2023 | 14 |
| NCT05857878Healthy · Belgium | 1 | Completed | Jun 6, 2024 | 59 |
| NCT05337592Healthy · Germany | 1 | Completed | Oct 18, 2022 | 72 |
How it is read
Names in the registry
- “BI 1815368”, 5 entries
- “BI 1815368 (C-14)”, 1 entry
- “BI 1815368 (C-13)”, 1 entry
- “BI 1815368 formulation 1”, 1 entry
- “BI 1815368 formulation 2”, 1 entry
Codes read as this program: BI1815368.
Conditions, from the studies’ own filings
- Macular Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.